Jeanmarie Guenot, Ph.D.
President & Chief Executive Officer
Jeanmarie Guenot, Ph.D. has 25 years of experience in the pharmaceutical and biotechnology industries. She has worked at both public and private companies, and across research and development, corporate development and venture capital. Among her achievements are several noteworthy bio-pharma mergers/acquisitions and licensing deals. Her experience spans small molecules and proteins and a variety of therapeutic areas including inflammation, autoimmune disease, oncology, cardiology, metabolic diseases, ophthalmology and neurology. She has more recently focused in immuno-oncology and specifically, in T cell engagement and bi-specific antibody drug development. Since 2013, Dr. Guenot has been the President & CEO of Amphivena Therapeutics, Inc., a clinical stage company developing a novel CD33 x CD3 bispecific antibody therapeutic for acute myeloid leukemia and myelodysplastic syndrome. She also co-founded Harpoon Therapeutics in 2015 and was its founding CEO and President. She co-founded Maverick Therapeutics in 2016, a spinout of Harpoon, and executed a build-to-buy deal with Takeda in January 2017 which comprised $125 million in funding including R&D support, option fee and equity investment.
Prior to her current role, Dr. Guenot co- founded, built and ran SKS Ocular, a start-up ophthalmic company incubator, focused on dry AMD, sustained release ocular drug delivery technologies and therapeutics for glaucoma, macular degeneration and ocular inflammation. She was a business advisor for Hoffmann-La Roche in Basel and Shanghai, and she was Vice President of Corporate & Business Development at PDL BioPharma, where she led licensing, mergers and acquisitions and alliance management for PDL’s R&D and commercial product portfolios. She led and negotiated the Biogen Idec-PDL 50:50 co-development and co-commercialization strategic collaboration, which involved three Phase 2 cancer and autoimmune disease drug candidates. This $800 M transaction included a $100 M equity investment in PDL and a therapeutic candidate with indications split between Biogen Idec/PDL and Hoffmann-La Roche. She also licensed the ophthalmic indication for the oncology drug to Ophthotech. She has portfolio, project and alliance management experience in the areas of oncology, cardiovascular diseases, autoimmune diseases, neurology and ophthalmic diseases.
Dr. Guenot started her business career at Atlas Venture, where she managed venture capital investments and built life science companies. She started her scientific career as a principal scientist in Preclinical R&D at Hoffmann-La Roche, discovering and developing drugs for metabolic diseases, inflammation, autoimmune diseases and oncology. Dr. Guenot trained in physical and medicinal chemistry, with a focus in quantum mechanical and semi-empirical methods for molecular dynamics, protein structure prediction, X-ray and NMR refinement and drug design. She earned her Ph.D. from the University of California, San Francisco and her MBA from The Wharton School at the University of Pennsylvania.
Eric J. Feldman, M.D.
Chief Medical Officer
Eric J. Feldman, M.D. is internationally recognized for his work in the development of new therapies for the treatment of leukemias and related bone marrow disorders. Dr. Feldman joins Amphivena from the clinical research group at Seattle Genetics, Inc. where he oversaw the myeloid leukemia antibody-drug conjugate (ADC) program. Dr. Feldman has had an extensive academic career, most recently as Professor of Medicine and Director of the Hematological Malignancies Service at Weill-Cornell/New York Presbyterian Hospital. He has led or participated in the conduct of numerous clinical trials, several leading to FDA approval including imatinib (GLEEVEC®) in chronic myeloid leukemia, lenalidomide (REVLIMID®) in myelodysplastic syndrome, and most recently, CPX-351 (VYXEOS™) in acute myeloid leukemia. Dr. Feldman has focused throughout his career on the clinical development of CD33-targeted therapies including lintuzumab (ZAMYL™), gemtuzumab ozogamicin (MYLOTARG™), and most recently, vadastuximab talirine (SGN-CD33A). In addition to his faculty appointment at Weill-Cornell, he has served on the faculty at New York Medical College and the University of Texas, MD Anderson Cancer Center. Dr. Feldman has authored over 150 scientific articles and is currently Editor-in Chief of the journal Leukemia Research.
Tae H. Han, Ph.D.
Vice President, Clinical Pharmacology & Translational Medicine
Tae H. Han, Ph.D. has extensive experience with nonclinical and clinical development for both small molecule drugs and antibody-based therapeutics. Before joining Amphivena, Dr. Han led the clinical pharmacology, DMPK, and toxicology functions at AbbVie Stemcentrx and was the South San Francisco site lead for clinical pharmacology and pharmacometrics at AbbVie, Inc. There, he supported the development of rovalpituzumab tesirine, a targeted ADC against cancer stem cells in small cell lung cancer, in addition to supporting the overall pipeline of antibody-drug conjugates for the treatment of solid tumor cancers. Prior to AbbVie Stemcentrx, Dr. Han was the head of clinical pharmacology at Seattle Genetics, Inc. and was the clinical pharmacology and DMPK lead for the world-wide approval of ADCETRIS™, an ADC for the treatment of Hodgkin and anaplastic large cell lymphoma. In addition, Dr. Han supported the development of lintuzumab (SGN-33, ZAMYL™) and vadastuximab talirine (SGN-CD33A) during his time at Seattle Genetics. Prior to working on antibody-drug conjugates, Dr. Han supported preclinical and clinical drug development of small molecule and peptide drugs in multiple therapeutic areas including metabolic, cardiovascular, and neuroscience at Merck and Co., Inc. Dr. Han received his B.S. in Chemical Engineering from the University of Washington, and Ph.D. in Chemical and Biomolecular Engineering from the University of California, Los Angeles where he also trained as a post-doctoral fellow in the School of Medicine, Division of Cardiology.
Sheryl Martin-Moe, Ph.D.
Head of CMC & Quality
Sheryl Martin-Moe, Ph.D. has more than 28 years of experience in the industry and has managed the development of over 100 diverse drugs and combination products. She has significantly contributed to the development and commercialization of Kogenate FS, rFVIII®, Nutropin NuSpin®, Perjeta® and Kadcyla® as well as numerous lifecycle formats for Nutropin AQ®, TNKase®, Lucentis®, Xolair® etc.
Sheryl is an Executive Vice President at Enterprise Catalyst Group (ECG) in Santa Rosa, CA. Prior to joining ECG and Amphivena, Sheryl was Global Head of Pharmaceutical Development at Novartis Biologics in Basel. Previously to that, she was at Genentech (Director of Late Stage Formulation, Device Development and Drug Product Processing Development), Bayer Biotechnology (Director of Formulation Development, Analytical Development, Clinical QC and Clinical Manufacturing of drug Substance and Drug Product), Centocor Diagnostics (Manager of Technical Support and Manufacturing) and Sterling Drug/Eastman Pharmaceuticals (Sr. Research Scientist). Sheryl has been a Visiting Scholar in the Chemistry and Biochemistry Dept. at the University of Delaware and was a postdoctoral fellow in Biochemistry at the University of California, Berkeley. Her Ph.D. is in Cell Biology from the University of Vermont.
Sheryl was a member/ co-author of the CMC Biotech Working Group for the A-Mab Case Study for Quality by Design and has co-edited a book on Quality by Design for Pharmaceutical Development. Her publications include 2 patents, 2 book chapters and 21 papers and invited presentations, including a publication that won the Parenteral Drug Association Frederick Simon Award.